Fernández Pinilla C, Luque Otero M, Martell Claros N, Alcázar de la Osa J M, Rodicio Díaz J L, Ruilope Urioste L M
Unidad de Hipertensión, Hospital Universitario San Carlos, Madrid.
Med Clin (Barc). 1993 Jun 26;101(5):168-71.
Hypertension and hypercholesterolemia are frequently associated with this leading to considerable cardiovascular risk.
An open parallel randomized study was performed in which the effects of doxazosin, an alpha-adrenergic blocker and enalapril, an inhibitor of the angiotensin converting enzyme were compared in 70 patients with essential high blood pressure and plasma cholesterol levels greater than 240 mg/dl. Following 2-4 weeks of placebo administration the patients were randomly treated with one of the two drugs. When required doses were increased and hydrochlorothiazide added until blood pressure lower than 160/95 mmHg was achieved. After this period the patients were observed for a minimum of 8 weeks. The mean length of the study was of 22 weeks.
Both drugs significantly reduced blood pressure without modifying cardiac frequency. Doxazosin tended to favorably modify the lipid profile of the plasma while enalapril significantly reduced the levels of cholesterol, lipids and high density lipoproteins (HDL). Upon termination of the study the total HDL/cholesterol index increased 8.6% in those treated with doxazosin and decreased 5.5% in those receiving enalapril (p < 0.05).
Although doxazosin and enalapril are potent antihypertensive drugs, the effects on plasma lipid obtained with doxazosin indicate that a reduction in cardiovascular risk was achieved with this drug in the patients included in this study.
高血压和高胆固醇血症常与此相关，导致相当大的心血管风险。
进行了一项开放平行随机研究，比较了70例原发性高血压且血浆胆固醇水平高于240mg/dl患者中，α-肾上腺素能阻滞剂多沙唑嗪和血管紧张素转换酶抑制剂依那普利的效果。在给予2-4周安慰剂后，患者被随机给予两种药物之一。必要时增加剂量并加用氢氯噻嗪，直至血压降至160/95mmHg以下。在此期间后，对患者至少观察8周。研究的平均时长为22周。
两种药物均显著降低血压，且不改变心率。多沙唑嗪倾向于改善血浆脂质谱，而依那普利显著降低胆固醇、脂质和高密度脂蛋白（HDL）水平。研究结束时，多沙唑嗪治疗组的总HDL/胆固醇指数增加8.6%，依那普利治疗组降低5.5%（p<0.05）。
尽管多沙唑嗪和依那普利都是有效的降压药物，但多沙唑嗪对血浆脂质的影响表明，在本研究纳入的患者中，该药物降低了心血管风险。
